Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Posted: August 22, 2024 at 2:32 am
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05 PM ET.
Originally posted here:
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Posted in Global News Feed
Comments Off on Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
Posted: August 22, 2024 at 2:32 am
Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws.
Read the rest here:
Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
Posted in Global News Feed
Comments Off on Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
Rose Hill Announces Addition of Two Senior Advisors to Advisory Team
Posted: August 22, 2024 at 2:32 am
Burton J. Tabaac MD, FAHA and Rotem Petranker, M.A. Set to Bolster Rose Hill’s Psychedelic Research Efforts Burton J. Tabaac MD, FAHA and Rotem Petranker, M.A. Set to Bolster Rose Hill’s Psychedelic Research Efforts
Read more here:
Rose Hill Announces Addition of Two Senior Advisors to Advisory Team
Posted in Global News Feed
Comments Off on Rose Hill Announces Addition of Two Senior Advisors to Advisory Team
Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain
Posted: August 22, 2024 at 2:32 am
PALO ALTO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has allowed numerous claims from U.S. patent application no. 17/562,229 and will issue a new patent containing those claims related to the treatment of acute pain (the “Patent”), to Scilex in late 2024, further strengthening the Company’s intellectual property position and coverage for its acute migraine treatment drug product, ELYXYB®, a liquid, micro-encapsulation formulation of celecoxib. The Patent, titled “Methods of Treating Pain,” covers methods of treating acute pain.
Posted in Global News Feed
Comments Off on Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management…
Posted: August 22, 2024 at 2:32 am
NCD Will Integrate Firefly’s BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes NCD Will Integrate Firefly’s BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes
Posted in Global News Feed
Comments Off on Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management…
Eyenovia Announces Pricing of $5.14 Million Public Offering
Posted: August 22, 2024 at 2:32 am
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering").
Original post:
Eyenovia Announces Pricing of $5.14 Million Public Offering
Posted in Global News Feed
Comments Off on Eyenovia Announces Pricing of $5.14 Million Public Offering
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY…
Posted: August 22, 2024 at 2:32 am
GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
See the original post here:
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY...
Posted in Global News Feed
Comments Off on BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY…
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
Posted: August 22, 2024 at 2:32 am
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), announced today that an independent screening of drugs for monkeypox (“Mpox”) highlighted cepharanthine’s potential to bind to the virus’s proteins. The letter to the editor titled, "Highly accurate protein structure prediction and drug screen of monkeypox virus proteome", is non peer reviewed and published in Journal of Infection and can be found here.
Read more from the original source:
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
Posted in Global News Feed
Comments Off on PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
Orion Corporation: Managers’ transactions – Niclas Lindstedt
Posted: August 22, 2024 at 2:32 am
ORION CORPORATION MANAGERS’ TRANSACTIONS 21 AUGUST 2024 at 18.45 EEST
View post:
Orion Corporation: Managers’ transactions – Niclas Lindstedt
Posted in Global News Feed
Comments Off on Orion Corporation: Managers’ transactions – Niclas Lindstedt
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
Posted: August 22, 2024 at 2:32 am
COPENHAGEN, Denmark, August 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract of 440,000 doses to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed European country.
Continued here:
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
Posted in Global News Feed
Comments Off on Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
